Tuesday, March 6, 2012
Endocyte Inc., of West Lafayette, Ind., said the FDA approved its importation of a supply of Doxil (doxorubicin) from Europe for a Phase III trial (PROCEED). The trial began in May 2011, but the company stopped enrollment because of global shortages of Doxil. PROCEED compares EC145 in combination with Doxil to Doxil alone for ovarian cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.